Get the Daily Brief
Latest Biotech News
Arvinas PROTAC shows CNS penetration: LRRK2 degraded in CSF
Arvinas reported Phase 1 multiple‑dose data for ARV‑102, a PROTAC degrader targeting LRRK2, showing approximately ≥50% reduction of LRRK2 protein in cerebrospinal fluid by day 14 that was...
In vivo CAR‑T clears tumors in mice: Azalea posts Nature paper
Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, reported preclinical in vivo CAR‑T results in Nature showing that systemically delivered gene‑editing particles can reprogram host T...
DNA Script expands SYNTAX reach: distributors in Latin America and East Asia
DNA Script signed distribution agreements with Gencell, Bio‑Medical Science Co. (BMS), and BioStream to expand global access to its benchtop SYNTAX platform for on‑demand single‑strand DNA oligo...
Crossbow raises $77M to push T‑cell engagers into clinic
Crossbow Therapeutics closed a $77 million Series B co‑led by Taiho Ventures and Arkin BioCapital to advance next‑generation T cell engager programs, including lead candidate CBX‑250 developed...
White House lifts NIH spending hold: agency cleared to spend 2026 budget
The Office of Management and Budget lifted a previous apportionment restriction, allowing the National Institutes of Health to access its full 2026 appropriations and resume awarding new grants....
SBIR/STTR funding reauthorized: Congress preserves seed grants for biotech
Congress passed a five‑year reauthorization of the SBIR and STTR programs, restoring federal seed funding that many small biotech firms rely on to reach commercialization milestones. The House...
FDA will consider RMATs for therapies on clinical hold – policy shift
The FDA announced it will consider regenerative medicine advanced therapy (RMAT) designations for candidate cell and gene therapies even when those programs are under clinical hold. The procedural...
Leica, Bio‑Techne automate RNAscope on BOND‑PRIME: US launch
Leica Biosystems and Bio‑Techne announced the U.S. launch of RNAscope automation on Leica’s BOND‑PRIME staining platform, enabling fully automated RNAscope RNA in‑situ hybridization (ISH) with...
J&J wins FDA nod for psoriasis pill – First oral IL‑23 blocker cleared
Johnson & Johnson secured U.S. Food and Drug Administration approval for icotrokinra, to be marketed as Icotyde, in patients 12 and older with moderate to severe plaque psoriasis. The approval...
Azalea’s in vivo CAR‑T clears tumors in mice: Nature paper shows proof
Azalea Therapeutics and collaborators published results in Nature demonstrating successful in vivo generation of CAR‑T cells after systemic delivery of gene‑editing particles, producing tumor...
White House lifts NIH spending hold — Grants, hiring to resume
The Office of Management and Budget (OMB) approved NIH apportionments, ending a hold that had constrained the agency’s ability to issue new research grants. NIH Director Jayanta 'Jay' Bhattacharya...
Basecamp, Anthropic, PacBio launch Trillion Gene Atlas: AI‑driven biodiversity push
Basecamp Research announced a Trillion Gene Atlas initiative in partnership with Anthropic, Ultima Genomics, Pacific Biosciences and Nvidia to massively expand environmental sequencing for...
Arvinas’ PROTAC hits brain target — ARV‑102 reduces LRRK2 in CSF >50%
Arvinas reported Phase 1 multiple‑dose data showing ARV‑102, an oral PROTAC degrader targeting LRRK2, achieved approximately 50% or greater reduction of LRRK2 protein in cerebrospinal fluid at all...
Crossbow banks $77M to advance TCR‑mimetic T‑cell engagers
Crossbow Therapeutics closed a $77 million Series B co‑led by Taiho Ventures and Arkin BioCapital to advance next‑generation T‑cell engagers into the clinic. The financing will support the Phase 1...
Structure posts injectable‑like oral GLP‑1 results — 44‑week Phase 2 shows ~16% weight loss
Structure Therapeutics disclosed Phase 2 results for aleniglipron, an oral once‑daily GLP‑1 receptor agonist, reporting up to roughly 16% placebo‑adjusted weight loss at 44 weeks. The company...
Engineered E. coli sustains intratumoral NO — Vascular normalization boosts anti‑PD‑L1 responses
Two independent reports published in Nature Biotechnology and Nature detail engineered Escherichia coli Nissle 1917 strains programmed with synthetic arginine–nitric oxide (NO) circuits that...
FDA clears Myriad’s MyChoice CDx as companion for GSK’s Zejula
Myriad Genetics received FDA approval for MyChoice CDx as a companion diagnostic to identify homologous recombination deficiency (HRD) and BRCA‑mutant advanced ovarian cancer patients eligible for...
Roche plans massive 'AI factory' — Nvidia deal to accelerate drug and diagnostic R&D
Roche announced a major expansion of its AI infrastructure in collaboration with Nvidia to accelerate drug discovery, diagnostics and biomanufacturing workflows. The company said it will deploy...
J&J’s Icotyde wins FDA approval — oral psoriasis option cleared
Johnson & Johnson announced FDA approval of icotrokinra, to be marketed as Icotyde, for moderate-to-severe plaque psoriasis in patients 12 and older. The agency’s decision converts a once-daily...
PROTAC reaches the brain... Arvinas posts central LRRK2 degradation
Arvinas presented Phase 1 multiple-dose data showing ARV-102, an oral PROTAC targeting LRRK2, achieved roughly 50% or greater reduction of LRRK2 protein in cerebrospinal fluid by day 14 and...